Immunogenicity and safety of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine: a systematic review.

Lv, Jingjing; Wu, Hui; Xu, Junjie; Liu, Jiaye

Lv, Jingjing; Wu, Hui; Xu, Junjie; Liu, Jiaye.

Afiliação

Lv J; Expanded Program Immunization Division of Shandong Provincial Center for Disease Control and Prevention, Shandong Provincial Key Laboratory of Infectious Disease Control and Prevention, Jinan, 250014, China.
Wu H; Nosocomial Infection Control Department, Shenzhen University General Hospital, Shenzhen, 518071, China.
Xu J; Clinical Research Academy, Peking University Shenzhen Hospital, Peking University, Shenzhen, 518036, China.
Liu J; School of Public Health, Shenzhen University Health Science Center, No. 1066 Xueyuan Avenue, Shenzhen, 518060, China. liujiaye1984@163.com.

Infect Dis Poverty ; 11(1): 53, 2022 May 13.

Article em En | MEDLINE | ID: mdl-35562753

Assuntos

Vacinas contra COVID-19; COVID-19; Anticorpos Neutralizantes; Anticorpos Antivirais; Vacina BNT162; COVID-19/prevenção & controle; Vacinas contra COVID-19/efeitos adversos; ChAdOx1 nCoV-19; Humanos; RNA Mensageiro; SARS-CoV-2; Vacinação; Vacinas Sintéticas; Vacinas de mRNA

Palavras-chave

COVID-19; Heterologous vaccination; Homologous vaccination; Immunogenicity; Safety

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 / 4_TD Base de dados: MEDLINE Assunto principal: Vacinas contra COVID-19 / COVID-19 Tipo de estudo: Systematic_reviews Limite: Humans Idioma: En Revista: Infect Dis Poverty Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google